ROARABLE
Today โŒ˜ Pro Terminal Big Ideas ๐ŸŽฒ Predictions Screener ๐Ÿฆ‹ Butterfly 8 Analysts ๐Ÿ›๏ธ Policy ๐ŸŽฌ Video โ˜… Watchlist ๐ŸŽฒ Prediction Markets ๐Ÿ“Š RQD Track Record ๐Ÿ“… Next Catalysts ๐Ÿ›ก๏ธ Overlap & Crash X-Ray ๐Ÿ“ฐ Live Wire ๐Ÿ‹ 13F Whales ๐Ÿ›๏ธ Congress & CEO Buys ๐Ÿ† $100K Arena โŒ˜ Pro Terminal ๐Ÿ“ Methodology & Corrections
Stock Ratings / Health Care / LNSR / dividends
QTEX (31) MBOT (41) DAVI (47) SKIN (36) โŒ˜ Pro Terminal โ†’

LENSAR Inc. (LNSR) Dividend Safety Gauge & 10-Year DRIP Compounder

$5.84 -2.18% NASDAQ โ€ข Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.81

LENSAR Inc. (LNSR) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

๐Ÿ“Š Historical Track Record Warning: Scores below 50 (24/100 ยท E) historically underperformed SPY in 71% of rolling 90-day windows โ†’
ROARABLE E โ€ข RED ALERT Cap $73.3M
๐Ÿ“ค Share Live RQD Speedometer Card: ๐• Post Reddit StockTwits โฌ‡ Live SVG Card
โšก INSTANT AI QUANT PREVIEW โ€ข $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LNSR Below โ€” or Connect Your Own ChatGPT / Claude
๐Ÿค– Mara Quenwick โ€ข AI Quant Lead (Click for Instant Brief) Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
โ–ผ

As of 2026-11-02, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $5.84 (-2.18% 1D, market cap $73.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LNSR ranks #956 in composite RQD confidence.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Ellis Vennor โ€ข AI Peer & Flow Quant (Click for Instant Brief) How does LNSR compare to QTEX and MBOT in the Health Care sector?
โ–ผ

Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– Gideon Ashmere โ€ข AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LNSR?
โ–ผ

Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

โœ“ Pre-computed one-to-many AI Quant brief
๐Ÿค– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists โ€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
๐Ÿ›ก๏ธ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.81 (-0.58%)๐Ÿงฌ Dilution Drag (+2.48% YoY Shares)โš™๏ธ Cash Engine: 3/20 (E) โ€ข 0% FCF Margin
Verify 90D Bucket Audit โ†’
๐Ÿ“Š Historical Track Record Warning: Scores below 50 (24/100 ยท E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY โ€ข 29.0% hit rate).
Audit Bucket Track Record โ†’
RQD QUANT TACHOMETERRED ALERT โ€ข E
025507510024
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0โ€“100 RQD rubric) โ€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E ยท Rk E
Cash (3)Whales (8)SEC (5)Macro (6)CEO (3)
Each axis scored 0โ€“20
12M PRICE TARGET CONE-15.2% Base Target
$14 Bull$5 Base$4 Bear
๐Ÿ“ฌ FREE LNSR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: โ€” (No Active Options Snapshot on file for LNSR)Realized 20D OHLCV Swing Band: ยฑ7%
Deterministic 5-Pillar Attribution (24/100 Composite)
๐Ÿ” WHY LNSR SCORES 24/100 (E) โ€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
โ–ฒ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (33% of score)

20D Institutional Volume Accumulation (ยฑ7% realized swing band)

โ–ฒ #2 Bullish Driver: Macro Regime Fit+6/20 pts (25% of score)

FRED Regime ร— Technicals: 11% of 52W Range โ€ข RSI-14 at 34.6 (NEUTRAL RANGE)

โ–ผ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

๐Ÿ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 โ†’ Q2 โ†’ Q3 โ†’ Current
Q1 (-3Q)
32
Grade E$6.37-8.9% Next Q
Q2 (-2Q)
29
Grade E$5.80+4.7% Next Q
Q3 (-1Q)
27
Grade E$6.07-3.8% Next Q
Current
24
Grade E$5.84-10.9% Hist 90D ฮฑ
Trajectory: E (32) โ†’ E (24)Full Audit โ†’
โš”๏ธ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

โš”๏ธ Adversarial Opposing Case: What Could Spark a LNSR Turnaround Squeeze

Gideon Ashmere Forensic Desk โ†’

While LNSR currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

๐Ÿš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

๐Ÿš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.10) and Max Pain ($6.13) forces dealer call-delta covering toward $13.59.

๐Ÿš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

๐ŸŽฒ LIVE PREDICTION MARKET ODDS TIED TO $LNSRโ€ข $2.4M Crowd Pool โ€ข Kalshi / Polymarket Composite
Contract: โ€œLNSR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMAโ€
YES 24%NO 76%Trade / Inspect Odds โ†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 โ€ข REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (7.4% EST. ANNUAL)

$10,000 Compounded Over 10 Years โ†’ $20,419

Est. Year-10 Shareholder Yield: $123/yr
$10.7K
Yr 1
$11.5K
Yr 2
$12.4K
Yr 3
$13.3K
Yr 4
$14.3K
Yr 5
$15.3K
Yr 6
$16.5K
Yr 7
$17.7K
Yr 8
$19.0K
Yr 9
$20.4K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP โ€ข SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LNSR)

  • โœ“Walkthrough of LNSR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • โœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • โœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) โ†’$100K Arena
LNSR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.66%๐Ÿ›ก๏ธ HOLDING TREND SUPPORT
2026-10-30O $6.00H $6.03L $5.76C $5.84VOL 28.8K
RES: $7.20SUP: $5.77SMA50: $7.10SMA200: $7.45
$11.39$9.65$7.90$6.15$4.41RES $7.20SUP $5.77$5.842026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LNSR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

๐Ÿฆ‹ LNSR Butterfly Map โ†’ + Track LNSR โ†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LNSR today. View full Setup Ledger โ†’

๐Ÿฆ‹ Documented & Second-Order Butterfly Connections Open Graph โ†’

No direct multi-tier Butterfly edges indexed yet for LNSR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
๐ŸŽฌ No recent verified company-specific video clip queued for LNSR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk โ†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT โ€ข SEC EDGAR XBRL ร— RQD PEER BENCHMARK

๐Ÿ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LNSR)

Health Care Rank #956 of 1016 โš”๏ธ QTEX vs LNSR Full Matrix โ†’

1. Head-to-Head Health Care Peer Comparison (LNSR vs. QTEX, MBOT, DAVI, SKIN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, LENSAR Inc. (LNSR) ranks #956 by composite RQD confidence (24/100, grade E) and #700 by equity capitalization ($73.3M). Within this direct 5-issuer industry benchmark cohort, LNSR leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and โ€” gross margin. DAVI currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with LNSR at 24/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LNSR ACTIVE
LENSAR Inc.
E 24/100 โ€” 39.4% -35.0% -2.18% $73.3M Benchmark Subject
QTEX
QTREX Quantum Ltd.
E 31/100 โ€” 0.7% -35.0% -7.58% $73.9M /qtex-vs-lnsr โ†’
MBOT
Microbot Medical Inc.
D- 41/100 โ€” โ€” -15.8% -2.68% $75.2M /mbot-vs-lnsr โ†’
DAVI
Davion Healthcare Plc
D 47/100 โ€” โ€” โ€” -37.55% $67.3M /davi-vs-lnsr โ†’
SKIN
SkinHealth Systems Inc. (Class A)
D- 36/100 โ€” 65.3% -26.9% -2.07% $66.0M /skin-vs-lnsr โ†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023โ€“FY2025)

SEC EDGAR 10-K โ€ข FILED 2025-12-31 โ€ข CIK 0001320350

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LENSAR Inc. (LNSR) reported GAAP revenue of $51.7M (+12.4% vs. FY2024 revenue of $46.0M , and +44.6% cumulative change since FY2023) , GAAP net income of -$34.3M, operating cash flow of -$14.8M, and free cash flow of -$14.9M (-513.5% YoY). On the balance sheet, LNSR closed FY2025 with $71.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $51.7M -$34.3M -$14.8M -$14.9M $71.4M โ€”
FY2024 (FY) 2024-12-31 $46.0M -$31.4M -$2.3M -$2.4M $66.3M โ€”
FY2023 (FY) 2023-12-31 $35.7M -$14.4M -$9.7M -$9.7M โ€” โ€”

3. LNSR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

โœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $5.84 (-2.18% 1D, market cap $73.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LNSR ranks #956 in composite RQD confidence.

How does LNSR compare to QTEX and MBOT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, QTEX (QTREX Quantum Ltd.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $73.9M) and MBOT (Microbot Medical Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -15.8%, cap $75.2M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LNSR?

Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LNSR trading relative to its 50-day, 200-day, and 52-week technical levels?

LNSR last traded at $5.84 (-2.18% on volume of 28,839 shares), positioning the stock -17.75% below its 50-day simple moving average ($7.10) and -21.61% below its 200-day simple moving average ($7.45). Across its 52-week range of $4.95 to $12.94, LNSR sits at the 11.1% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ยฑ7.0% ($5.43 to $6.25).

LNSR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS โ€ข SEC EDGAR ร— CBOE ร— FRED

Does LNSR pay a dividend and is it safe?

LENSAR Inc. (LNSR) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: LNSR RQD Cockpit LNSR 12M Forecast LNSR Earnings & Move LNSR Dividends & DRIP LNSR Insiders & 13F LNSR Whale Options LNSR Profit Sankey LNSR News & Why
ROARABLE RATING BRIEF โ€ข RQD 24/100 (E) โœ“ STAGE-C NUMBER FIREWALL VERIFIED

LNSR โ€” LENSAR Inc.: What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1
As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, LENSAR Inc. (LNSR) carries a composite score of 24 / 100 (E โ€” Roarable Strong Sell โ€” Forensic Risk / Avoid).\n- Fundamental Cash Engine (2 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of -20.33% and gross margin of 39.4%.\n- Institutional 13F Whale Flow (8 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Medical/Dental Instruments cohort.\n- Insider & Congressional Conviction (3 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (6 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (5 / 20): Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt-to-Equity of 0.50.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %\n------------------------------\n$5.84$73.3MN/AN/AN/AN/A0.00%1.00$4.95 - $12.94-35.0%

Business & Sector Positioning

LENSAR Inc. (LNSR) is a NASDAQ-listed Health Care issuer operating in Medical/Dental Instruments with a market capitalization of $0.1B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Medical/Dental Instruments (Health Care), LNSR exhibits an operating margin of -47.6% and net margin of -60.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (39.4%), and valuation discipline (current multiple) relative to free cash flow conversion.

Open Questions for Prospective Investors

  • How sustainable is LNSR's current operating margin (-47.6%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Medical/Dental Instruments?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 0.20)?

LNSR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LENSAR Inc. (LNSR) โ€ข Click "Debate This Headline" to argue it in the Roar Pit below

๐Ÿ’ฌ Jump to LNSR Debate Forum (3) โ†“
๐ŸŸข CATALYST Yahoo Finance โ€ข 80d ago
LENSAR Q2 Earnings Call Highlights

LENSAR (NASDAQ:LNSR) reported second-quarter 2026 revenue growth of 18% as the company continued to rebuild commercial momentum following the termination of its proposed merger with Alcon near the end of the first quarte

Read Full Source โ†—
๐Ÿ”ด RISK WATCH Yahoo Finance โ€ข 153d ago
Lensar (LNSR) Q1 2026 Earnings Transcript

Nick Curtis, Chief Executive Officer; and Tom Staab, Chief Financial Officer of LENSAR, who will provide an overview of recent developments, our go-forward strategy and financial results. Before we begin, I'd like to rem

Read Full Source โ†—
๐Ÿ”ฅ THE ROAR PIT โ€ข LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LNSR Bull vs. Bear Conversation Board โ€” What's Your Call at $5.84?

๐Ÿ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LNSR ๐Ÿป 67% BEARISH CONVICTION
1. Pick Your Side on LNSR:
๐Ÿ’ก Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ๐Ÿป BEARISH ๐ŸŽฏ Target: $5.14 (-12.0%)
๐Ÿ“Œ Pinned Debate

๐Ÿ”ฅ Official Bull vs. Bear Debate: Is LNSR (E โ€ข RQD 24/100) a Buy at $5.84?

Welcome to the LNSR (LENSAR Inc.) Roar Pit. Current RQD Composite is 24/100 (Roarable Strong Sell โ€” Forensic Risk / Avoid) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (๐Ÿ‚ Bull or ๐Ÿป Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch ๐Ÿป BEARISH ๐ŸŽฏ Target: $4.67 (-20.0%)
Spot @ $5.84

Pump the brakes on LNSR โ€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LNSR, but look at what you are paying: current EV/EBITDA multiples with 39.4% gross margins. Unless LENSAR Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader ๐Ÿ‚ BULLISH ๐ŸŽฏ Target: $7.18 (+22.9%)
Spot @ $5.84

LNSR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LNSR, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.84 (52-wk range $4.95 - $12.94), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%